StemRIM Inc
TSE:4599
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
326
699
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
StemRIM Inc
Common Shares Outstanding
StemRIM Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
StemRIM Inc
TSE:4599
|
Common Shares Outstanding
ÂĄ61.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
TSE:2160
|
Common Shares Outstanding
ÂĄ50.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
||
PeptiDream Inc
TSE:4587
|
Common Shares Outstanding
ÂĄ129.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
||
Takara Bio Inc
TSE:4974
|
Common Shares Outstanding
ÂĄ120.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
||
Pharma Foods International Co Ltd
TSE:2929
|
Common Shares Outstanding
ÂĄ28.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
||
C
|
Cuorips Inc
TSE:4894
|
Common Shares Outstanding
ÂĄ8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
StemRIM Inc
Glance View
StemRIM, Inc. engages in the research and development of regeneration inducing medicine. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 46 full-time employees. The company went IPO on 2019-08-09. The firm is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
See Also
What is StemRIM Inc's Common Shares Outstanding?
Common Shares Outstanding
61.5m
JPY
Based on the financial report for Jul 31, 2024, StemRIM Inc's Common Shares Outstanding amounts to 61.5m JPY.
What is StemRIM Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
7%
Over the last year, the Common Shares Outstanding growth was 1%. The average annual Common Shares Outstanding growth rates for StemRIM Inc have been 1% over the past three years , 7% over the past five years .